Eliem Therapeutics Inc (NASDAQ: ELYM)
$7.04
+0.0500 ( +0.71% ) 255.5K
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).
Market Data
Open
$7.04
Previous close
$6.99
Volume
255.5K
Market cap
$471.51M
Day range
$6.93 - $7.55
52 week range
$2.35 - $11.55
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
prem14a | Proxies and info statements | 10 | May 17, 2024 |
10-q | Quarterly Reports | 59 | May 15, 2024 |
10-k/a | Quarterly Reports | 16 | Apr 29, 2024 |
8-k | 8K-related | 41 | Apr 11, 2024 |
4 | Insider transactions | 1 | Apr 08, 2024 |
10-k | Annual reports | 73 | Mar 28, 2024 |
4 | Insider transactions | 1 | Mar 20, 2024 |
8-k | 8K-related | 15 | Mar 19, 2024 |
4 | Insider transactions | 1 | Mar 04, 2024 |
10-q | Quarterly Reports | 57 | Nov 14, 2023 |